Phase 2 RCT in 130 patients with advanced soft tissue sarcoma after anthracyclines: trabectedin-olaparib vs trabectedin gave 6-month PFS of 32% vs 28% (HR 0.722, P=0.081), meeting the P<0.10 threshold but with marginal benefit; more grade 3+ blood toxicity.
RCTn = 130
D'Ambrosio et al. Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group